Filtered By:
Specialty: Cardiology
Condition: Heart Failure
Drug: Diovan

This page shows you your search results in order of date.

Order by Relevance | Date

Total 17 results found since Jan 2013.

Angiotensin Receptor-Neprilysin Inhibitor Effects on Atherosclerotic Cardiovascular Disease Events: A Meta-Analysis of Randomized Controlled Trials
In conclusion, this meta-analysis found no association between ARNI therapy and improved ASCVD events in patients with HF.PMID:37619492 | DOI:10.1016/j.amjcard.2023.07.154
Source: Atherosclerosis - August 24, 2023 Category: Cardiology Authors: Lis Victoria Ravani Douglas Mesadri Gewehr Pedro Calomeni Mateus de Miranda Gauza Jussara Pereira Rhanderson Cardoso Henrique Barbosa Ribeiro Edimar Bocchi Source Type: research

Angiotensin Receptor –Neprilysin Inhibitor Effects on Atherosclerotic Cardiovascular Disease Events: A Meta-Analysis of Randomized Controlled Trials
Sacubitril-valsartan is an angiotensin receptor –neprilysin inhibitor (ARNI) associated with a decreased risk of death and hospitalization for selected patients with heart failure (HF). However, its association with improved atherosclerotic cardiovascular disease (ASCVD) events remains unclear. We performed a meta-analysis to evaluate the assoc iation of ARNI with ASCVD events in patients with HF. We systematically searched PubMed, Embase, Cochrane, and ClinicalTrials.gov for studies comparing ARNIs with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in terms of myocardial infarc...
Source: The American Journal of Cardiology - August 22, 2023 Category: Cardiology Authors: Lis Victoria Ravani, Douglas Mesadri Gewehr, Pedro Calomeni, Mateus de Miranda Gauza, Jussara Pereira, Rhanderson Cardoso, Henrique Barbosa Ribeiro, Edimar Bocchi Source Type: research

Haemodynamic Effects of Sacubitril/Valsartan Initiation in Outpatients with Chronic Heart Failure
ConclusionThe vasodilative effects of S/V result in immediate reductions in SVRI, SBP, SV and CI. However, S/V induces reverse cardiac remodelling, which is apparent shortly after treatment initiation and leads to improvements of clinical, functional, echocardiographic, laboratory and haemodynamic variables.
Source: American Journal of Cardiovascular Drugs - September 22, 2022 Category: Cardiology Source Type: research

Left ventricular output indices and sacubitril/valsartan titration: role of stroke volume index
ConclusionsStroke volume index is positively associated with complete titration of sacubitril/valsartan. Patients with low SVi are more prone to experience hypotension during titration
Source: ESC Heart Failure - March 23, 2022 Category: Cardiology Authors: Paolo Tolomeo, Ottavio Zucchetti, Emanuele D'Aniello, Noemi Punzo, Federico Marchini, Luca Di Ienno, Elisabetta Tonet, Rita Pavasini, Claudio Rapezzi, Gianluca Campo, Matteo Serenelli Tags: Short Communication Source Type: research

Effects of Blood Pressure Lowering Agents on Cardiovascular Outcomes in Weight Excess Patients: A Systematic Review and Meta-analysis
ConclusionsIn hypertensive subjects with excess weight, diuretics are more effective for preventing HF and stroke than CCB and ACEI, respectively. CCB are a good first-line choice for prevention of cardiovascular disease, except HF.
Source: American Journal of Cardiovascular Drugs - January 2, 2020 Category: Cardiology Source Type: research

Sacubitril-Valsartan versus Standard Anti-Hypertensives in Left Ventricular Assist Device Patients
Hypertension is a common comorbidity affecting patients with left ventricular assist devices (LVAD). Left uncontrolled, it may lead to a decrease in LVAD support and increase the risk for stroke. The ISHLT defines hypertension in LVAD patients as a mean arterial pressure (MAP) of> 90 mmHg and recommends aggressive management utilizing standard heart failure medications. Sacubitril-valsartan (Entresto ®) is an angiotension II blocker-neprilysin inhibitor with potent anti-hypertensive effects approved for the treatment of heart failure with a reduced ejection fraction.
Source: Journal of Cardiac Failure - August 1, 2018 Category: Cardiology Authors: Erika Nicolsen, Lisa Curran, Stephanie Dixon, Molly Reece, Sarah Herbert, Amy Clegg, Michael Tillery, Daniel Bensimhon, Dalton McLean Tags: 070 Source Type: research

Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.
CONCLUSION: Effective reduction of blood pressure to accepted goals is the key to reduce the risk of CV events and stroke. Dual inhibition of neprilysin and the angiotensin receptor with sacubitril/valsartan may represent an attractive and serendipitous therapeutic approach for a range of CV diseases, including hypertension and HF, in which vasoconstriction, volume overload and neuro-hormonal activation play a part in pathophysiology. Sacubitril/Valsartan appears to be more efficacious in reducing blood pressure than currently available ACEi and ARBs with a similar safety and tolerability profile. Besides, pleiotropic bene...
Source: Indian Heart J - July 1, 2018 Category: Cardiology Authors: Dargad RR, Prajapati MR, Dargad RR, Parekh JD Tags: Indian Heart J Source Type: research

Sacubitril/Valsartan: A Novel Angiotensin Receptor-Neprilysin Inhibitor
Conclusion Effective reduction of blood pressure to accepted goals is the key to reduce the risk of CV events and stroke. Dual inhibition of neprilysin and the angiotensin receptor with sacubitril/valsartan may represent an attractive and serendipitous therapeutic approach for a range of CV diseases, including hypertension and HF, in which vasoconstriction, volume overload and neuro-hormonal activation play a part in pathophysiology. Sacubitril/Valsartan appears to be more efficacious in reducing blood pressure than currently available ACEi and ARBs with a similar safety and tolerability profile. Besides, pleiotropic benef...
Source: Indian Heart Journal - January 9, 2018 Category: Cardiology Source Type: research

Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure?
Heart failure and diabetes commonly coexist, and therefore, drugs that favorably influence the natural history of each of these two disorders are likely to be prescribed together.1 In patients with type 2 diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists decrease the risk of major adverse cardiovascular events,2,3 and liraglutide is approved to reduce cardiovascular death, nonfatal myocardial infarction and nonfatal stroke.4 Analogously, in patients with chronic heart failure and a reduced ejection fraction, neprilysin inhibition has been shown to decrease the risk of cardiovascular death and hospitalization for ...
Source: Journal of Cardiac Failure - January 3, 2018 Category: Cardiology Authors: Milton Packer Tags: Editorial Source Type: research

Abstract P421: The Effects of Dual Angiotensin Receptor and Neprilysin Inhibitor on Organoprotection in Experimental Model of Chronic Heart Failure Session Title: Renin-Angiotensin System
The cardiac effects of dual angiotensin receptor and neprilysin inhibitor (LCZ696) as a novel therapeutic approach for inhibition of renin-angiotensin system was assessed in volume overload-induced chronic heart failure (CHF) in hypertensive Ren2 transgenic rats (TGR) with aorto-caval fistula (ACF) and compared with valsartan (VAL). CHF model was induced by ACF in male TGR at 8 weeks of age. After 5 weeks of ACF induction, LCZ696 was administered in standard dosing at 68 mg/kg/day and VAL at 31 mg/kg/day for next 15 weeks to assess the effect on mortality. In second series, 12 weeks after ACF, the animals were anaesthetize...
Source: Hypertension - September 14, 2017 Category: Cardiology Authors: Libor Kopkan, Lenka Hoskova, Voȷtech Melenovsky, Zuzana Huskova, Ludek Cervenka Tags: Poster Abstract Presentations Source Type: research

The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF
Conclusions Compared with enalapril, sacubitril/valsartan reduced the risk of both the primary endpoint and a coronary composite outcome in PARADIGM-HF. Additional studies on the effect of sacubitril/valsartan on atherothrombotic outcomes in high risk patients are merited.
Source: American Heart Journal - March 14, 2017 Category: Cardiology Source Type: research

Focus on the Novel Cardiovascular Drug LZC696: from Evidence to Clinical Consideration
AbstractLCZ696, a first-in-class angiotensin receptor neprilysin inhibitor (ARNI), is comprised of the angiotensin receptor blocker valsartan and the neprilysin inhibitor pro-drug sacubitril (AHU377). After oral administration, AHU377 is rapidly metabolized to the active neprilysin inhibitor LBQ657. LCZ696 exerts its effects of diuresis, natriuresis, vasodilation and aldosterone secretion inhibition through simultaneous renin-angiotensin-aldosterone system (RAAS) blockade and natriuretic peptides system (NPS) enhancement. Powerful evidence including PARAMETER and PRARDIGM-HF trials have shown that LCZ696 outperforms RAAS i...
Source: Cardiovascular Drugs and Therapy - November 17, 2016 Category: Cardiology Source Type: research

Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial
Conclusions In the high CV risk, hypertensives of the VALUE trial reducing BP consistently to <140/90 mmHg had marked beneficial effects both when data were calculated as proportion of visits at BP target or as on-treatment mean BP. Reducing BP to <130/80 mmHg led only to some possible further benefit on stroke, whereas the risk of other outcomes remained substantially similar to or slightly greater than that seen at the higher target. Thus, aggressive BP reductions when CV risk is high may not offer substantial advantages, except perhaps in patients or conditions in which stroke risk is particularly common.
Source: European Heart Journal - March 21, 2016 Category: Cardiology Authors: Mancia, G., Kjeldsen, S. E., Zappe, D. H., Holzhauer, B., Hua, T. A., Zanchetti, A., Julius, S., Weber, M. A. Tags: Hypertension Source Type: research

Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial
Conclusion The infrastructure of GCS and the primary health care system in Iran enabled the conduct of this pragmatic large-scale trial. If the polypill strategy proves effective, it may be implemented to prevent cardiovascular disease in developing countries.
Source: European Journal of Preventive Cardiology - November 9, 2015 Category: Cardiology Authors: Ostovaneh, M. R., Poustchi, H., Hemming, K., Marjani, H., Pourshams, A., Nateghi, A., Majed, M., Navabakhsh, B., Khoshnia, M., Jaafari, E., Mohammadifard, N., Malekzadeh, F., Merat, S., Sadeghi, M., Naemi, M., Etemadi, A., Thomas, G. N., Sarrafzadegan, N. Tags: Original scientific paper Source Type: research

Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
ConclusionsIn VALIANT, the risk of HF following MI was higher in women than men after adjusting for age and comorbidities, although the risk of other fatal and non‐fatal outcomes were similar. The higher long‐term risk of HF in women appears to be independent of the extent of left ventricular systolic dysfunction or remodelling compared with men.
Source: European Journal of Heart Failure - February 6, 2015 Category: Cardiology Authors: Carolyn S. P. Lam, Margaret McEntegart, Brian Claggett, Jiankang Liu, Hicham Skali, Eldrin Lewis, Lars Køber, Jean Rouleau, Eric Velazquez, Rob Califf, John J. McMurray, Marc Pfeffer, Scott Solomon Tags: Original Article Source Type: research